Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01116778
Other study ID # MA0809005101
Secondary ID
Status Completed
Phase Phase 3
First received April 30, 2010
Last updated August 31, 2015
Start date May 2010
Est. completion date June 2012

Study information

Verified date August 2015
Source GenMont Biotech Incorporation
Contact n/a
Is FDA regulated No
Health authority Taiwan: Center for Drug EvaluationTaiwan: Department of HealthTaiwan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of probiotics eN-Lac® capsules (Lactobacillus paracasei GMNL-32) for the treatment of children with perennial allergic rhinitis(PAR).


Description:

This study is PhaseIII clinical trial. According the results of PhaseII study,we find out the optimal dose and its maximum effectiveness in relieving the nasal symptoms of eN-LacĀ® (Lactobacillus paracasei GMNL-32) in children with PAR.


Recruitment information / eligibility

Status Completed
Enrollment 236
Est. completion date June 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 16 Years
Eligibility Inclusion Criteria

- Subjects in age of 5-16 years old

- Subjects with a history of perennial allergic rhinitis for at least 1 year.

- Subjects with anyone of the following allergy test results (test results within 12 months before study are acceptable)

- Skin-Prick test:

Wheal diameter 3 mm larger than the negative control (salt water) and at least 1/2 the diameter of the positive control (histamine)

- Positive reaction determined by the CAP system Positive reaction defined as CAP score=2

- Positive reaction determined by the MAST system Positive reaction defined as MAST score=1

- Subject's mean nasal total symptom score (NTSS) throughout the screening period (4 to 10 days) should be = 5 and = 10; at least 3 days should be recorded during the screening period

- Subjects' parents or their legally acceptable representatives have signed the informed consent form.

Exclusion Criteria

- Subjects have clinically significant laboratory abnormality results (hematology, biochemistry or urinalysis tests) as determined by the investigator (tests performed during 14 days prior to visit 1 or during baseline period can be used for evaluating those criteria).

- Subjects with acute or significant chronic sinusitis, severe persistent asthma, congenital immunodeficiency, massive wound in oral cavity, use of rhinitis medications, neuropsychiatric disorders, immunocompromised, or chronic use of tricyclic antidepressants.

- Subjects need to take prohibited medications during the study or take the medications within the corresponding time frame indicated prior to the screening visit:

Parenteral or oral corticosteroids 30 days Nasal corticosteroids 30 days Topical use of flurandrenolide 30 days Topical use of clobetasol propionate 30 days Topical use of halobetasol propionate 30 days Astemizole 30 days Ketotifene 21 days Nedocromil or Sodium cromoglycate 14 days Loratadine 10 days Cetirizine 7 days Antileukotrienes 7 days Other H1 antihistamine 3 days Nasal decongestant 3 days Any food supplements including probiotics 3 days

- Subjects are undergoing desensitization therapy within 3 months prior to the screening period or subjects with vasomotor rhinitis.

- Subjects have participated investigational drug trial within 4 weeks before entering this study.

- Subjects are pregnant, lactating or planning to become pregnant.

- Subjects with any other serious diseases considered by the investigator that could interfere with the performance of NTSS result.

- Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.

- Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
eN-Lac®
One capsule with 2x10^9 colony forming unit (cfu) LP GMNL-32, once daily, po
Other:
Placebo
One placebo capsule, once daily, po

Locations

Country Name City State
Taiwan Chang Gung Children's Hospital Taipei
Taiwan MacKay Memorial Hospital Taipei
Taiwan Taipei City Hospital Renai Branch Taipei
Taiwan Cardinal Tien Hospital Xindian Taipei

Sponsors (2)

Lead Sponsor Collaborator
GenMont Biotech Incorporation Biomedical Development Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the efficacy profile of probiotics Lactobacillus paracasei GMNL-32 (eN-Lac®) in children with perennial allergic rhinitis. NTSS is determined by the severity of allergic symptoms, including sneezing, rhinorrhea, nasal itching, and nasal stuffiness. These symptoms are evaluated using a four-point scale, namely, 0 = Absent, 1 = Mild (present but not disturbing), 2 = Moderate (disturbing but not hampering daytime activities and/or sleep), 3 = Severe (hampering daytime activities and/or sleep). NTSS is calculated by the sum of the scores of the symptoms. NTSS is recorded daily on subject's DRC (daily record card) at the 8th week from baseline. No
Secondary The safety features are evaluated through the changes of vital signs, physical examinations, laboratory test result (hematology, biochemistry and urinalysis tests), as well as the occurrence of adverse event. The incidence of adverse events will be categorized by severity and related to the time of occurrence. Changes in physical examinations, changes in laboratory test results (hematology, biochemistry and urinalysis tests) from screening period, and change of vital signs will be summarized and analyzed by the descriptive statistics. at 8th week from basline Yes
See also
  Status Clinical Trial Phase
Completed NCT01654536 - A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR) Phase 4
Completed NCT01539304 - Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis Phase 3
Completed NCT01221285 - Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium Phase 1
Terminated NCT00491374 - Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED) Phase 4
Completed NCT00783224 - A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512) Phase 3
Completed NCT04324918 - Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis Phase 3
Completed NCT02532179 - Subcutaneous Immunotherapy for Mouse in Adults Phase 1/Phase 2
Completed NCT01451541 - A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). Phase 3
Enrolling by invitation NCT01062139 - Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy Phase 4
Completed NCT00405899 - Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections N/A
Completed NCT01549340 - Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022) N/A
Completed NCT01018862 - A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis Phase 3
Completed NCT00789555 - Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis Phase 4
Completed NCT00261287 - Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) Phase 3
Completed NCT00974571 - Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246) Phase 3
Completed NCT04654702 - Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
Completed NCT05122143 - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers N/A
Completed NCT01380327 - Biomarkers of Cockroach Sublingual Immunotherapy 2 Phase 1/Phase 2
Completed NCT00359216 - The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726) Phase 4
Completed NCT00163514 - Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403) Phase 3